143 related articles for article (PubMed ID: 4514333)
1. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
Dietrichson P
Acta Neurol Scand Suppl; 1972; 51():111-3. PubMed ID: 4514333
[No Abstract] [Full Text] [Related]
2. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
Holmsen R; Kvan L; Presthus J; Thoresen GB
Acta Neurol Scand Suppl; 1972; 51():121-2. PubMed ID: 4514336
[No Abstract] [Full Text] [Related]
3. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
[No Abstract] [Full Text] [Related]
4. Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
Pekkarinen A; Rinne UK; Salokangas R; Siirtola T; Sonninen V
Acta Neurol Scand Suppl; 1972; 51():129-30. PubMed ID: 4514339
[No Abstract] [Full Text] [Related]
5. Dopa-decarboxylase inhibitors.
Lancet; 1973 May; 1(7810):979-80. PubMed ID: 4121597
[No Abstract] [Full Text] [Related]
6. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
Streifler M; Vardi J; Kesten M
Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
[No Abstract] [Full Text] [Related]
7. Recent advances in the treatment of Parkinsonism with drugs.
Rinne UK
Acta Neurol Scand Suppl; 1972; 51():59-103. PubMed ID: 4576076
[No Abstract] [Full Text] [Related]
8. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
[No Abstract] [Full Text] [Related]
9. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Gehlen W; Eisenlohr JJ
Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
[No Abstract] [Full Text] [Related]
10. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Birkmayer W; Linauer W; Mentasti M; Riederer P
Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
[No Abstract] [Full Text] [Related]
11. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
Gattringer B; Steinhäusl H
Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
[No Abstract] [Full Text] [Related]
12. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
Stammler A; Vielhaber K
Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
[No Abstract] [Full Text] [Related]
13. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
De Divitiis E; Cerillo A; Tata MR; Decina A
Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
[No Abstract] [Full Text] [Related]
14. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
Klawans HL; Ringel SP; Shenker DM
J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
[TBL] [Abstract][Full Text] [Related]
15. Levodopa and pressor amine sensitivity in parkinsonism.
Reid JL; Calne DB; George CF; Vakil SD
Clin Pharmacol Ther; 1972; 13(3):400-6. PubMed ID: 5026378
[No Abstract] [Full Text] [Related]
16. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
Christiani K; Möller WD
Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
[No Abstract] [Full Text] [Related]
17. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
Miller EM; Wiener L
Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107
[No Abstract] [Full Text] [Related]
18. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
Dietrichson P
Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
[No Abstract] [Full Text] [Related]
19. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; de Ajuriaguerra J
Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
[No Abstract] [Full Text] [Related]
20. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
Marsden CD; Barry PE; Parkes JD; Zilkha KJ
J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):10-4. PubMed ID: 4691682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
